Cardiovascular Risk Assessment in Primary Prevention

1. Auflage 2022
ISBN: 978-3-030-98823-4
Verlag: Springer Nature Switzerland

Buch, Englisch, 513 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 1054 g

Reihe: Contemporary Cardiology

This book is the first comprehensive text dedicated to risk assessment in the primary prevention of atherosclerotic cardiovascular disease. It provides an overview of current evidence regarding approaches to risk assessment, traditional and emerging risk factors, and atherosclerosis imaging for refinement of risk estimation. The volume seeks to provide an essential resource for professionals in the field to assess their patients for risk of cardiovascular disease. 
The book is divided into five sections, starting off with an overview of current best practices to risk assessment in primary prevention around the world. The second section discusses traditional risk factors, such as hypercholesterolemia, hypertension, diabetes, smoking, and obesity. The third section reviews the newly introduced concept of ‘Risk Enhancers’. The fourth section offers insight on novel risk factors, with in-depth discussion regarding lipoprotein(a), high-sensitivity CRP, apolipoproteinB, social determinants of health, stress and cardiovascular disease. and polygenic risk scores. The final section covers the use of non-invasive atherosclerosis imaging (computed tomography and ultrasound-based techniques) as a tool to refine risk estimates. Throughout the book, readers will find multiple tables, figures, and illustrations that complement the text. 

Up-to-date, evidence-based, and clinically oriented, Cardiovascular Risk Assessment in Primary Prevention is a must-have resource for physicians, residents, fellows, and medical students in cardiology, endocrinology, primary care, and health promotion and disease prevention.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Shapiro, Michael D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Public Health, Gesundheitsmanagement, Gesundheitsökonomie, Gesundheitspolitik

Inhaltsverzeichnis

Part 1 - Global Approaches to Risk Assessment.- 1. Cardiovascular Risk Assessment in Primary Prevention.- 2. Global Approaches to Risk Assessment – the U.S. Guidelines.- 3. European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease.- Part 2 - Traditional Risk Factors.- 4. Hypercholesterolemia.- 5. Blood pressure control in primary care.- 6. Cardiovascular Risk Assessment in Metabolic Syndrome and Diabetes.- 7. Primary Prevention: Smoking.- 8. At the Heart of the Matter: Obesity and its Interplay with Preventive Cardiology.- Part 3 - Risk Enhancers.- 9. Family History of Premature Atherosclerotic Cardiovascular Disease.- 10. Primary Prevention and Cardiovascular Risk Assessment in Women.- 11. Ethnic Factors in the Assessment of Cardiovascular Risk for Primary Prevention.- 12. Triglycerides Rich-Lipoproteins.- 13. "Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus for Prevention".- 14. Chronic Kidney Disease is a Risk Enhanced for Cardiovascular Diseases.- 15. Peripheral Arterial Disease and The Ankle Brachial Index.- Part 4 - Novel Risk Factors.- 16. Lipoprotein(a).- 17. High-Sensitivity C-Reactive Protein.- 18. Apolipoprotein B in Primary Prevention: Ready for Time Prime?.- 19. Social Determinants of Cardiovascular Health.- 20. Stress and Cardiovascular Disease.- 21. Polygenic Risk Scores.- Part 5 - Atherosclerosis Imaging as a Tool to Refine Risk Estimates.- 22. Coronary Artery Calcium.- 23. Cardiac Computed Tomography Angiography for Prevention of Cardiovascular Events.- 24. Carotid Intima-Media Thickness and Plaque Assessment.

Über Autor(innen)

Michael Shapiro is the inaugural Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest University where he is on faculty in the Section of Cardiovascular Medicine. After completing a cardiology fellowship, Michael spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital/Harvard Medical School.  After training, he was on faculty in the Knight Cardiovascular Institute at Oregon Health & Science University. He served as Director of Atherosclerosis Imaging and Associate Director of the Center for Preventive Cardiology. In 2019, he transitioned to Wake Forest University where he serves as the Director of the Center for Prevention of Cardiovascular Disease and the Co-Director of the NIH T32 Cardiovascular Disease Epidemiology and Prevention Research Fellowship Program.

Michael's clinical interests revolve around genetic and acquired disorders of cholesterol and triglycerides, atherosclerosis imaging, genetic predisposition to early myocardial infarction, and cardiovascular risk assessment. Michael has published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology. The scope of his research spans translational science, cardiovascular epidemiology, and clinical trials of novel lipid modulating therapeutics. He also serves as a principal investigator on numerous clinical trials testing novel lipid modulating therapeutics.